Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 22, 2022 - Issue 11
Submit an article Journal homepage
826
Views
0
CrossRef citations to date
0
Altmetric
Editorial

What are the key considerations for deciding on the use of CAR T-cell therapy for patients with follicular lymphoma?

Bradley HunterLDS Hospital, Salt Lake City, Utah, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9184-2737View further author information
ORCID Icon
Pages 1159-1161 | Received 23 Aug 2022, Accepted 25 Sep 2022, Published online: 08 Oct 2022

References

  • Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017 Oct 19;130(16):1800–1808.
  • Salles GA, Schuster SJ. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Aug. 2022;16. DOI: 10.1182/bloodadvances.2022008150.
  • Ghione P, Palomba ML, Patel A, et al. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Jun. 2022;9. DOI: 10.1182/blood.2021014375.
  • Kanters S, Kahl BS, Wiesinger A, et al. Clinical outcomes in patients relapsed/refractory after ≥ 2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis. J clin oncol. 2021;39(15_suppl):e19548–e19548.
  • Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022 Jan;23(1):91–103.
  • Neelapu S, Chavez J, Sehgal A, et al. Long-Term Follow-up Analysis of Zuma-5: a phase 2 study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-hodgkin lymphoma (iNHL). Trans Cell Ther Meetings; 2022; Salt Lake City.
  • Fowler NH, Dickinson M, Dreyling M, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Feb. 2022;28(2):325–332.
  • Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531–2544.
  • Wang M, Munoz J, Goy A. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 Study J Clin Oncol . Jun 4 2022;2102370. DOI: 10.1200/JCO.21.02370
  • Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. Feb. 2022 17;386(7):640–654.
  • Bishop MR, Dickinson M, Purtill D, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. Feb. 2022 17;386(7):629–639.
  • Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018 Feb 1;378(5):439–448.
  • Budde LE, Assouline S, Sehn LH, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-Cell lymphomas: phase I dose-escalation study. J clin oncol. 2022;40(5):481–491.
  • Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. The Lancet. Haematology. 2022 May;95:e327–e339. e327-e339.
  • Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021 Sep 25;398(10306):1157–1169.
  • Hutchings M, Morschhauser F, Iacoboni G. Glofitamab, a novel, bivalent CD20-Targeting T-Cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-Cell lymphoma: a phase i trial. Jun. 2021. 20. 39(18):1959–1970.
  • Falchi L, Offner F, Belada D, et al. First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): phase 1/2 data update. J clin oncol. 2022;40(16_suppl):7523.
  • Falchi L, Leppä S, Wahlin BE, et al. Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): update from phase 1/2 trial. J clin oncol. 2022;40(16_suppl):7524.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.